CoChat
Sign Up
Cited by 147Circadian rhythm and melatoninAntioxidant Activity and Oxidative StressDiabetes Treatment and Management

RETRACTED: Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial

Raygan, Fariba, Ostadmohammadi, Vahidreza, Bahmani, Fereshteh, Reiter, Russel J., Asemi, Zatollah·2019·Clinical Nutrition
DOI 10.1016/j.clnu.2017.12.004
Open this paper in CoChat — free account

Abstract

Background & aims Melatonin may benefit diabetic people with coronary heart disease (CHD) through its beneficial effects on biomarkers of oxidative stress and cardio-metabolic risk. This investigation evaluated the effects of melatonin administration on metabolic status in diabetic patients with CHD.Methods This randomized, double-blind, placebo-controlled trial was conducted and involved 60 diabetic patients with CHD. Subjects were randomly allocated into two groups to receive either 10 mg melatonin (2 melatonin capsules, 5 mg each) (n = 30) or placebo (n = 30) once a day for 12 weeks.Results Compared with the placebo, melatonin supplementation resulted in significant increases in plasma glutathione (GSH) (+64.7 ± 105.7 vs. -11.1 ± 137.6 μmol/L, P = 0.02) and nitric oxide (NO) (+0.9 ± 4.7 vs. -3.3 ± 9.6 μmol/L, P = 0.03), and significant decreases in malondialdehyde (MDA) (-0.2 ± 0.3 vs. +0.1 ± 0.5 μmol/L, P = 0.007), protein carbonyl (PCO) (-0.12 ± 0.08 vs. +0.03 ± 0.07 mmol/mg protein, P < 0.001) and serum high sensitivity C-reactive protein (hs-CRP) levels (-1463.3 ± 2153.8 vs. +122.9 ± 1230.4 ng/mL, P = 0.001). In addition, taking melatonin, compared with the placebo, significantly reduced fasting plasma glucose (-29.4 ± 49.0 vs. -5.5 ± 32.4 mg/dL, P = 0.03), serum insulin concentrations (-2.2 ± 4.1 vs. +0.7 ± 4.2 μIU/mL, P = 0.008), homeostasis model of assessment-estimated insulin resistance (-1.0 ± 2.2 vs. +0.01 ± 1.6, P = 0.04), total-/HDL-cholesterol ratio (-0.18 ± 0.38 vs. +0.03 ± 0.35, P = 0.02) and systolic (-4.3 ± 9.6 vs. +1.0 ± 7.5 mmHg, P = 0.01) and diastolic blood pressure (-2.8 ± 7.3 vs. +0.1 ± 3.6 mmHg, P = 0.04). Melatonin treatment also significantly increased quantitative insulin sensitivity check index (+0.006 ± 0.01 vs. -0.004 ± 0.01, P = 0.01) and serum HDL-cholesterol (+2.6 ± 5.5 vs. -0.01 ± 4.4 mg/dL, P = 0.04). Supplementation with melatonin had no significant effect on other metabolic parameters.Conclusions Overall, melatonin intake for 12 weeks to diabetic patients with CHD had beneficial effects on plasma GSH, NO, MDA, PCO, serum hs-CRP levels, glycemic control, HDL-cholesterol, total-/HDL-cholesterol ratio, blood pressures and parameters of mental health. Registered under ClinicalTrials.gov Identifier no. http://www.irct.ir: IRCT2017051333941N1.

Integrity signals

Registry

Crossref · 10.1016/j.clnu.2017.12.004This paper is marked retracted.

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Raygan, F., Ostadmohammadi, V., Bahmani, F., Reiter, R. J., & Asemi, Z.
Affiliations
  • Kashan University of Medical Sciences (IR)
  • The University of Texas at San Antonio Health Science Center (US)
ORCID
Venue
Clinical Nutrition
Publisher
Elsevier BV
Published
2019-02
Volume
38
Issue
1
Pages
191-196
ISSN
0261-5614 (ISSN-L)
DOI
10.1016/j.clnu.2017.12.004
OpenAlex
W2774713064
Cited by
147
References
30
Citations by year
2026: 5 · 2025: 15 · 2024: 28 · 2023: 14 · 2022: 23 · 2021: 17 · 2020: 18 · 2019: 16 · 2018: 11
FWCI
7.55
Type
journal article
Language
en
Status
Retracted
Update notices
Open access
closed
Licence
Locations
  • Clinical Nutrition (publishedVersion)
  • PubMed (publishedVersion)
Funders
Vice-chancellor for Research, KUMS, Kashan, and Iran (96025)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
  • Health Sciences › Medicine › Biochemistry › Antioxidant Activity and Oxidative Stress
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
melatonin supplementation, type 2 diabetes, coronary artery disease, oxidative stress, cardiometabolic risk, insulin resistance, insulin sensitivity, lipid profile, C-reactive protein, inflammation, nitric oxide, glutathione, malondialdehyde, protein carbonyls, fasting blood glucose, serum insulin, HDL cholesterol, LDL cholesterol, HDL/HDL2 ratio, HDL2
MeSH terms
Aged, Aged, 80 and over, Antioxidants, Blood Glucose, Blood Pressure, C-Reactive Protein, Coronary Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glutathione, Humans, Insulin, Cholesterol, HDL, Male, Malondialdehyde, Melatonin, Middle Aged, Nitric Oxide, Biomarkers, Oxidative Stress

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review